Format

Send to

Choose Destination
J Infect. 2018 Mar;76(3):270-279. doi: 10.1016/j.jinf.2017.12.002. Epub 2017 Dec 15.

Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis-Burkina Faso, 2014-2015.

Author information

1
Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle, Ouagadougou, Burkina Faso. Electronic address: dinanibekambire@yahoo.fr.
2
Epidemic Intelligence Service, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA; National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA, USA. Electronic address: hzx8@cdc.gov.
3
Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle, Ouagadougou, Burkina Faso.
4
Ministère de la Santé, Ouagadougou, Burkina Faso.
5
Centre Hospitalier Universitaire-Yalgado Ouédraogo, Ouagadougou, Burkina Faso.
6
Centre Hospitalier Universitaire Sourou Sanou, Bobo-Dioulasso, Burkina Faso.
7
Centre Muraz, Bobo-Dioulasso, Burkina Faso.
8
National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA, USA.
9
Davycas International, Ouagadougou, Burkina Faso.
10
Laboratoire National de Santé Publique, Ouagadougou, Burkina Faso.

Abstract

OBJECTIVES:

We evaluate early impact of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis in Burkina Faso.

METHODS:

Nationwide surveillance gathered demographic/clinical information and cerebrospinal fluid (CSF) results for meningitis cases. Pneumococcal cases were confirmed by culture, polymerase chain reaction (PCR), or latex agglutination, and strains serotyped using PCR. We compared incidence (cases per 100,000) in the early post-PCV13 period (2014 and 2015) to average pre-PCV13 incidence (2011-2013).

RESULTS:

In 2015, age-specific pneumococcal meningitis incidences were 8.7 (<1 year), 2.4 (1-4 years), 6.5 (5-14 years), and 2.6 (≥15 years). Compared to 2011-2013, PCV13-serotype incidence among all ages decreased by 32% (95%CI: 23%-39%), with significant decreases among children aged <1 year (76%; 95%CI: 64%-84%) and 1-4 years (58%, 95%CI: 40%-71%). Among all ages, incidence of PCV13 serotypes besides serotype 1 decreased (68%; 95%CI: 59%-75%), but serotype 1 incidence did not. Incidence of non-PCV13 serotypes also decreased (47%; 95%CI: 29%-60%). Among children aged <1 year, serotypes 12F/12A/12B/44/46 (17%), 1 (12%), and 5 (10%) predominated.

CONCLUSIONS:

Following PCV13 introduction, PCV13-serotype meningitis incidence in young children significantly decreased. PCV13 impact on serotype 1 and disease in older children and adults requires continued monitoring.

KEYWORDS:

Burkina Faso; Meningitis; Pneumococcal conjugate vaccine; Pneumococcal meningitis; Surveillance; Vaccine impact

PMID:
29253559
PMCID:
PMC5821694
DOI:
10.1016/j.jinf.2017.12.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center